LISATA THERAPEUTICS, INC.
About LISATA THERAPEUTICS, INC.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $170.0K
- Net income
- -$16.6M
- Total assets
- $17.7M
- Market cap
- $30.5M
- Operating margin
- -10711.2%
- Net margin
- -9756.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $170.0K
- Operating expenses
- $18.4M
- Operating income
- -$18.2M
- Income tax
- -$962.0K
- Net income
- -$16.6M
- EPS (basic)
- $-1.91
- EPS (diluted)
- $-1.91
Balance sheet
- Total assets
- $17.7M
- Current assets
- $17.7M
- Total liabilities
- $3.1M
- Current liabilities
- $3.1M
- Shareholders’ equity
- $14.6M
Cash flow
- Operating cash flow
- -$15.9M
- Investing cash flow
- $15.1M
- Financing cash flow
- $599.0K
- Net cash flow
- -$253.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $30.5M
- EPS (diluted)
- $-1.91
- Shares outstanding
- 8.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 1, 1999
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $16.6M in FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LISATA THERAPEUTICS, INC..
Write a review
News about LISATA THERAPEUTICS, INC.
News & sentiment via Polygon.io
